These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 35950609

  • 1. Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic.
    Rahnama'i MS.
    Am J Mens Health; 2022; 16(4):15579883221115593. PubMed ID: 35950609
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of metastatic, castration-resistant prostate cancer].
    von Amsberg G, Merseburger AS.
    Urologe A; 2020 Jun; 59(6):673-679. PubMed ID: 32274540
    [Abstract] [Full Text] [Related]

  • 3. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
    Yoo M, Nelson RE, Haaland B, Dougherty M, Cutshall ZA, Kohli R, Beckstead R, Kohli M.
    J Natl Cancer Inst; 2023 Nov 08; 115(11):1374-1382. PubMed ID: 37436697
    [Abstract] [Full Text] [Related]

  • 5. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.
    J Urol; 2015 Dec 08; 194(6):1537-47. PubMed ID: 26196735
    [Abstract] [Full Text] [Related]

  • 6. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May 08; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 7. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K, Kramer G, Eymard JC, Sternberg CN, de Bono J, Castellano D, Tombal B, Wülfing C, Liontos M, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Oudard S, Facchini G, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, Bensfia S, de Wit R.
    Lancet Oncol; 2020 Nov 08; 21(11):1513-1525. PubMed ID: 32926841
    [Abstract] [Full Text] [Related]

  • 8. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J.
    Eur Urol; 2015 Aug 08; 68(2):317-24. PubMed ID: 25108579
    [Abstract] [Full Text] [Related]

  • 9. [Apalutamide, Erleada®].
    Sautois B, Denis C.
    Rev Med Liege; 2022 Oct 08; 77(10):609-615. PubMed ID: 36226398
    [Abstract] [Full Text] [Related]

  • 10. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.
    Eur J Cancer; 2013 Dec 08; 49(18):3821-30. PubMed ID: 24200698
    [Abstract] [Full Text] [Related]

  • 11. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
    Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G.
    Eur Urol; 2014 Sep 08; 66(3):459-65. PubMed ID: 24411987
    [Abstract] [Full Text] [Related]

  • 12. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May 08; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 13. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb 08; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 14. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
    Schmidt A, Anton A, Shapiro J, Wong S, Azad A, Kwan E, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua AM, Pook D, Gibbs P, Tran B, Weickhardt A.
    Asia Pac J Clin Oncol; 2021 Feb 08; 17(1):36-42. PubMed ID: 32970925
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wang L, Paller CJ, Hong H, De Felice A, Alexander GC, Brawley O.
    JAMA Oncol; 2021 Mar 01; 7(3):412-420. PubMed ID: 33443584
    [Abstract] [Full Text] [Related]

  • 16. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D, CARD Investigators.
    N Engl J Med; 2019 Dec 26; 381(26):2506-2518. PubMed ID: 31566937
    [Abstract] [Full Text] [Related]

  • 17. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
    González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA.
    Clin Transl Oncol; 2021 May 26; 23(5):969-979. PubMed ID: 33625671
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN, Castellano D, de Bono J, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, de Wit R.
    Eur Urol; 2021 Oct 26; 80(4):497-506. PubMed ID: 34274136
    [Abstract] [Full Text] [Related]

  • 19. [Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?].
    Thomas C, Ohlmann CH.
    Urologe A; 2020 Jun 26; 59(6):665-672. PubMed ID: 32274544
    [Abstract] [Full Text] [Related]

  • 20. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
    Suzuki H, Castellano D, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Foster MC, Ozatilgan A, Geffriaud-Ricouard C, de Wit R.
    Jpn J Clin Oncol; 2021 Aug 01; 51(8):1287-1297. PubMed ID: 33738495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.